Get the Stockscreener App
0.987
0.61%
0.006
After Hours:
1.00
0.013
+1.32%
Biofrontera Inc stock is traded at $0.987, with a volume of 227.08K.
It is up +0.61% in the last 24 hours and up +24.23% over the past month.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
See More
Previous Close:
$0.981
Open:
$0.98
24h Volume:
227.08K
Relative Volume:
1.31
Market Cap:
$12.64M
Revenue:
$43.20M
Net Income/Loss:
$-11.09M
P/E Ratio:
-0.8902
EPS:
-1.1088
Net Cash Flow:
$-9.32M
1W Performance:
+11.36%
1M Performance:
+24.23%
6M Performance:
+29.78%
1Y Performance:
+51.87%
1-Day Range:
$0.98
$1.0102
1-Week Range:
$0.8503
$1.03
52-Week Range:
$0.5547
$1.19
Biofrontera Inc Stock (BFRI) Company Profile
Name
Biofrontera Inc
Sector
Phone
781-245-1325
Address
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.987 | 12.64M | 43.20M | -11.09M | -9.32M | -1.1088 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Biofrontera Inc Stock (BFRI) Latest News
Biofrontera Inc (BFRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biofrontera Inc (BFRI) Institutional Confidence - TradingKey
Biofrontera Inc (BFRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biofrontera Inc (BFRIW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biofrontera Inc (BFRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biofrontera Inc (BFRI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biofrontera Inc (BFRI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biofrontera Inc (BFRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biofrontera Inc (BFRI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biofrontera Inc (BFRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biofrontera Shareholders Approve Director Elections and Equity Plan - TipRanks
Biofrontera (NASDAQ: BFRI) OKs directors, bigger incentive plan and auditor - Stock Titan
Biofrontera Inc (BFRIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biofrontera Inc (BFRIW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biofrontera Inc (BFRIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biofrontera Inc (BFRIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biofrontera Inc (BFRIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biofrontera Inc (BFRIW) Institutional Confidence - TradingKey
Biofrontera Inc (BFRIW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biofrontera Inc (BFRIW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BFRI News | BIOFRONTERA INC (NASDAQ:BFRI) - ChartMill
BFRI: All proposals, including director elections and plan amendments, were approved by shareholders - TradingView
Number of shareholders of Biofrontera Inc. – BOATS:BFRI - TradingView
Biofrontera Inc. Warrants (BFRIW) Stall at $0.03 as Trading Range TightensVolatility Stop - newsline.com
BFRI Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesHealthcare Earnings Report - newsline.com
BFRI Q1 2026 Earnings: Steep EPS Miss Weighs on Shares as Revenue Remains UnreportedGAAP Earnings Report - newsline.com
BFRI Q1 2026 Earnings: Significant EPS Miss Amid Operational ChallengesCEO Earnings Statement - newsline.com
Medicure: Q1 Earnings Snapshot - AOL.com
Bio-Path: Q1 Earnings Snapshot - AOL.com
Biofrontera Earnings Call Highlights Growth And Risks - TipRanks
Biofrontera (BFRI) Q1 2026 Earnings Transcript - The Motley Fool
BFRI Q1 2026 Earnings: Wider-than-Expected Loss as Stock Rises on Strategic ProgressEarnings Recovery Stocks - newsline.com
Number of shareholders of Biofrontera Inc. – NASDAQ:BFRIW - TradingView
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST QUARTER OF 2026 - TradingView
BFRI: Revenue and margins are rising as new indications and regulatory milestones drive future growth - TradingView
REX: Fiscal Q1 Earnings Snapshot - AOL.com
Squires Says Sun PGR Petition Denied For Not Naming Parent - Law360
Biofrontera Inc. Warrants (BFRIW) Surge Over 19% as Speculative Interest ReturnsInvestment Factor - The Legal Advocate
Ellomay: Q1 Earnings Snapshot - AOL.com
Biofrontera Inc. (BFRI) Edges Higher: A Small-Cap Biotech Finds Temporary FootingEntry Point Alerts - newsline.com
Biofrontera Inc. (BFRI) Faces Selling Pressure, Nearing Critical Support at $0.75TPO Profile - The Legal Advocate
BFRI Q1 2026 Earnings: Significant EPS Miss, Yet Stock Rises on Operating DisciplineMargin Improvement Report - newsline.com
BFRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid No Reported Revenue - The Legal Advocate
Biofrontera (BFRI) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Stock RisesRising Community Picks - Newser
BFRI Q1 2026 Earnings: Wide EPS Miss Fails to Dampen Investor SentimentNegative Surprise Momentum - newsline.com
Biofrontera to present at Lytham Partners Spring 2026 Investor Conference on May 28 - Pluang
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - The Manila Times
Squires Institutes 5 Patent Reviews, Rejects 7 Others - Law360
BFRI Downgraded by Benchmark -- Rating Maintained as Speculative Buy - GuruFocus
This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Biofrontera stock rating cut to Speculative Buy by Benchmark - Investing.com
Biofrontera Inc Stock (BFRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.23%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):